Top Tweets for #FirstDisclosure
Molecular Cancer Therapeutics highlights novel cancer therapies through its #FirstDisclosure article type. These articles present drugs for the first time in published literature. Check out recently published First Disclosures: https://t.co/55LlApNMse
New #FirstDisclosure in the June issue—Identification of CADM1 as an Immunotherapeutic Target and Evaluation of a Novel CADM1-Targeting Antibody–Drug Conjugate in Preclinical Osteosarcoma Models https://t.co/rG0F8f4jpQ #OpenAccess
Read the #FirstDisclosure featured on the cover of the June issue: Development of Antibody–Drug Conjugates Targeting L1CAM to Treat Metastatic Cancer https://t.co/a74aYfOHnJ @LabMassague @KarunaMDPhD @MSKCancerCenter
Molecular Cancer Therapeutics highlights novel cancer therapies through its #FirstDisclosure article type. These articles present drugs for the first time in published literature. Check out recently published First Disclosures: https://t.co/YmZbAz1DFn #ASCO26
Molecular Cancer Therapeutics highlights novel cancer therapies through its #FirstDisclosure article type. These articles present drugs for the first time in published literature. Check out recently published First Disclosures: https://t.co/B995eJeIIo
Read the #FirstDisclosure featured on the cover of the May issue: Preclinical Development and a Case Report of a Nanobody-Based CLDN18.2 CAR-T IMC002 with Reduced On-Target Off-Tumor Toxicity https://t.co/99FtG9DPZi
New #FirstDisclosure in the May issue—CHS-114: An Afucosylated Anti-CCR8 Monoclonal Antibody that Selectively Depletes Intratumoral Treg Cells and Induces Antitumor Immune Responses https://t.co/AmGBGNTrTo #OpenAccess
Online now! Simultaneous publication with an @AACR Annual Meeting 2026 poster: The #FirstDisclosure of ADCE-T02 – a Next Generation Antibody Drug Conjugate Targeting Tissue Factor Demonstrates Superior Preclinical Efficacy and Tolerability https://t.co/OLiLOS733p
#OpenAccess
Online now! Simultaneous publication with an #AACR26 poster: #FirstDisclosure of ABL209 (NEOK002), an EGFRxMUC1 bispecific TOP1i ADC with promising anti-tumor activity and enhanced therapeutic window https://t.co/lqrM70OLkH
Molecular Cancer Therapeutics highlights novel cancer therapies through its #FirstDisclosure article type. These articles present drugs for the first time in published literature. Check out recently published First Disclosures: https://t.co/EUtSgGJulF
#AACR26
Read the new #FirstDisclosure from the April issue: A Novel Dual-Payload ADC Platform Integrating #Exatecan and #Triptolide to Enhance Antitumor Efficacy and Overcome Resistance https://t.co/27F0xYFe3A
#AntibodyDrugConjugates #OpenAccess
New #FirstDisclosure from the April issue: Preclinical Development of MGC028, an ADAM9-Targeted, Glycan-Linked, Exatecan-Based #AntibodyDrugConjugate for the Treatment of Solid Cancers https://t.co/587wfRzJAY
New #FirstDisclosure in the March issue: HRA00129-C004, a Novel c-Met Antibody–Drug Conjugate, Exerts Encouraging Antitumor Activities and Favorable Safety Profiles https://t.co/TGD0QtkcaD
Read the #FirstDisclosure featured on cover of the March issue: Identification and Nonclinical Characterization of SAR444200, a Novel Anti-GPC3 NANOBODY T-cell Engager, for the Treatment of GPC3+ Solid Tumors https://t.co/yY6fcatHz9
#OpenAccess
New #FirstDisclosure in the February issue: TUB-010, a Novel Anti-CD30 Antibody–Drug Conjugate Based on Tub-Tag Technology, Widens the Therapeutic Window by Reducing Toxicity While Maintaining High Efficacy https://t.co/siMvrkqfS1
#MMAE
Read the #FirstDisclosure featured on cover of the February issue: Dual Inhibitors of #KRASG12D and #HSP90 Are Effective against KRASG12D Inhibitor Resistance, by Takeshi Shimamura and colleagues https://t.co/lgFA6YYVpm
@UICancerCenter @RanokTx
Molecular Cancer Therapeutics highlights novel cancer therapies through its #FirstDisclosure article type. These articles present drugs for the first time in published literature. Check out recently published First Disclosures: https://t.co/ipAVlTn3ug
Molecular Cancer Therapeutics highlights novel cancer therapies through its #FirstDisclosure article type. These articles present drugs for the first time in published literature. Check out recently published First Disclosures: https://t.co/BdHE7PhQy5
#FirstDisclosure Preclinical Characterization of XB010: A Novel Antibody–Drug Conjugate for the Treatment of Solid Tumors that Targets Tumor-Associated Antigen 5T4 https://t.co/VcIe9DoyPM
Molecular Cancer Therapeutics highlights novel cancer therapies through its #FirstDisclosure article type. These articles present drugs for the first time in published literature. Check out recently published First Disclosures: https://t.co/cV0tMlcJf5
Last Seen Hashtags on Sotwe
Trends for you
Most Popular Users
Elon Musk 
@elonmusk
240.6M followers
Barack Obama
@barackobama
119.2M followers
Donald J. Trump
@realdonaldtrump
111.7M followers
Cristiano Ronaldo
@cristiano
110.5M followers
Narendra Modi
@narendramodi
107M followers
Rihanna
@rihanna
97.6M followers
NASA
@nasa
92.2M followers
Justin Bieber
@justinbieber
90.9M followers
KATY PERRY
@katyperry
87.6M followers
Taylor Swift
@taylorswift13
81.4M followers
Lady Gaga
@ladygaga
72.9M followers
Virat Kohli
@imvkohli
69.8M followers
Kim Kardashian
@kimkardashian
69.8M followers
YouTube
@youtube
68.7M followers
Bill Gates
@billgates
63.8M followers
Neymar Jr
@neymarjr
62.5M followers
The Ellen Show
@theellenshow
62.4M followers
CNN
@cnn
61.9M followers
X
@x
60.8M followers
Selena Gomez
@selenagomez
60.7M followers